Background: Long-term air pollution exposure and inflammation are considered to be associated with cognitive decline. However, whether air pollution exposure related cognitive decline is dependent on inflammation remains uncertain.
Materials And Methods: The present study collected data from China Health and Retirement Longitudinal Study (CHARLS) at baseline in 2011, with a follow up period in 2015. Concentration of air pollutants (particles with diameters ≤ 1.0 μm [PM], ≤ 2.5 μm [PM], ≤ 10 μm [PM], nitrogen dioxide [NO] and ozone [O]) were obtained from China High Air Pollutants (CHAP) dataset. Hypersensitive C-reactive protein (hs-CRP), a systemic inflammation marker, was measured in blood of subjects and cognitive function was assessed by standardized questionnaire.
Results: A total of 6434 participants were included in the study. Lower exposure to PM, PM, PM and NO were associated with mitigated cognitive decline. The odds ratios (ORs) for air pollutants changes and cognitive decline and 95% confidence intervals (CIs) were as follows: PM-0.934(0.925, 0.943), PM- 0.945 (0.935,0.955), PM-0.977(0.972,0.982) and NO-0.962(0.950,0.975), respectively. Hs-CRP showed no significant correlation with cognitive decline or change in levels of air pollution. The interaction regression analyses, both unadjusted and adjusted, did not uncover any significant correlation between hs-CRP and air pollution with respect to cognitive decline. Bootstrap test exhibited no significant mediating effect of hs-CRP on the relationship between any air pollutants and cognitive decline, the indirect effects of hs-CRP in conjunction with exposure to different air pollutants were all found to be non-significant, with the following bootstrap CIs and p-values: PM-1.000([1.000,1.000], P = 0.480),PM-1.000([1.000,1.000], P = 0.230),PM-1.000([1.000,1.000], P = 0.650), O-1.000([1.000,1.000], P = 0.470), ΔNO-1.000([1.000,1.000], P = 0.830) .
Conclusion: Ambient air pollution exposure was linked to cognitive decline independent of hs-CRP level.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662488 | PMC |
| http://dx.doi.org/10.1186/s12940-024-01148-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of physical multimorbidity on cognitive decline trajectories among adults aged 50 years and older with different wealth status: a 17-year population-based cohort study.
Glob Ment Health (Camb)
January 2025
Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China.
This study aimed to investigate the effects of physical multimorbidity on the trajectory of cognitive decline over 17 years and whether vary across wealth status. The study was conducted in 9035 respondents aged 50+ at baseline from nine waves (2002-2019) of the English Longitudinal Study of Aging. A latent class analysis was used to identify patterns of physical multimorbidity, and mixed multilevel models were performed to determine the association between physical multimorbidity and trajectories of cognitive decline.
View Article and Find Full Text PDFAssessment of sensory impairment in older adults with dementia.
J Otol
October 2024
Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic.
Background: Over 55 million people worldwide are living with dementia. The rate of cognitive decline increases with age, and loss of senses may be a contributing factor.
Objectives: This study aimed to analyze hearing, olfactory function, and color vision in patients with dementia.
Symptom management in isocitrate dehydrogenase mutant glioma.
Neurooncol Pract
February 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality.
View Article and Find Full Text PDFUpdated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Alzheimers Dement
January 2025
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Introduction: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.
Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!